Get the Stockscreener App
1,191.77
0.95%
11.61
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,191.77, with a volume of 852.66K.
It is up +0.95% in the last 24 hours and up +1.04% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,180.16
Open:
$1175.2
24h Volume:
852.66K
Relative Volume:
0.29
Market Cap:
$1.06T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
42.90
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-3.30%
1M Performance:
+1.04%
6M Performance:
+14.99%
1Y Performance:
+69.89%
1-Day Range:
$1,163.50
$1,198.52
1-Week Range:
$1,163.50
$1,240.10
52-Week Range:
$685.15
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,191.30 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.49 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.26 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.97 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.36 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start - Yahoo Finance
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
Willis Investment Counsel Purchases 3,240 Shares of Eli Lilly and Company $LLY - MarketBeat
OmniAb partners with Eli Lilly on ion channel program - Investing.com
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Eli Lilly and Company $LLY Shares Acquired by Strive Financial Group LLC - MarketBeat
TD Asset Management Inc Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Qsemble Capital Management LP Trims Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY is Suncoast Equity Management's 5th Largest Position - MarketBeat
CRA looking into pharmaceutical giant Eli Lilly Canada's taxes - National Post
Eli Lilly and Company $LLY Position Lowered by Chilton Capital Management LLC - MarketBeat
Eli Lilly and Company $LLY Shares Bought by BCGM Wealth Management LLC - MarketBeat
Ascent Group LLC Purchases 1,544 Shares of Eli Lilly and Company $LLY - MarketBeat
LLY Looks 21.9% Undervalued on GF Value™ - GuruFocus
Oppenheimer Asset Management Inc. Has $95.32 Million Stock Position in Eli Lilly and Company $LLY - marketbeat.com
Eli Lilly and Company $LLY Shares Purchased by SWS Partners - MarketBeat
Boone County residents denied hearing on possible Eli Lilly pollutants - Goshen News
Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Raises 2026 Revenue Guidance, Is The Stock Still A Bargain? - simplywall.st
Eli Lilly (NYSE:LLY) stock in focus as obesity treatment demand lifts guidance - Kalkine Media
Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient - The Motley Fool
Eli Lilly’s Weight-Loss Pill Just Went Global. Is LLY Stock Too Late to Buy? - TIKR.com
Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’ - Stocktwits
Mill Capital Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Jennison Associates LLC Increases Position in Eli Lilly and Company $LLY - MarketBeat
Fire Capital Management LLC Has $2.54 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co (LLY) Gets a Buy from Barclays - The Globe and Mail
This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G - Healthcare Digital
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND) - The Globe and Mail
PRIMECAP Management Co trims Eli Lilly stake by 50K - TipRanks
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - fool.com
Eli Lilly and Company (NYSE:LLY) Trading Down 2.2%What's Next? - MarketBeat
Veeva Systems (VEEV) Could Be 24% Undervalued On Eli Lilly Global Vault CRM Rollout - simplywall.st
LLY Looks 21.8% Undervalued on GF Value™ - GuruFocus
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Eli Lilly sues companies that allegedly sold unapproved versions of new GLP-1 - BenefitsPRO
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug - AJMC
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - Yahoo Finance
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool
Eli Lilly (LLY) Files Six Lawsuits Over Illicit Retatrutide Sales - simplywall.st
Berenberg Bank Initiates Eli Lilly and Co(LLY.US) With Hold Rating, Announces Target Price $1,220 - Moomoo
Kirkland & Ellis Helps Eli Lilly Sue to Shut Down Alleged Black Market for GLP 1 - Law.com
Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate - Law360
Eli Lilly and Company (NYSE:LLY) Stays Tied To The Metabolic Health Story - Kalkine Media
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race - ca.finance.yahoo.com
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity - AOL.com
Eli Lilly targets booming black market for retatrutide - STAT
Novo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Eli Lilly Stock (LLY) Opinions on Q2 Earnings Results - Quiver Quantitative
Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope - TechStock²
Lilly veteran named director of IU Kelley School’s life sciences center - ibj.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):